Lisinopril Market Report 2026

Lisinopril Market Overview

• Lisinopril market size has reached to $1.87 billion in 2025 • Expected to grow to $2.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Rising Cardiovascular Disease Rates Drive Expansion Of Lisinopril Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lisinopril Market?

Lisinopril is a medication classified as an angiotensin-converting enzyme (ACE) inhibitor. It functions by reducing specific chemicals that constrict blood vessels, promoting smoother blood flow and enhancing the heart's ability to pump blood effectively. Lisinopril is prescribed to adults for the treatment of congestive heart failure and to increase survival rates following a heart attack. The main types of brands are lisinopril zestoretic, prinivil, zestril, and others. Zestoretic is a medication containing a fixed blend of two active components such as lisinopril, which acts as an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. The various diseases include hypertension, heart failure, heart attack, strokes, diabetic kidney disease, others with various dosages such as tablets, and liquid, and others with various population types including children, and adults. These are used by various end-users such as hospitals, specialty clinics, and others.

What Is The Lisinopril Market Growth Forecast?

The lisinopril market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising cardiovascular disease burden, growing demand for affordable generic drugs, increasing focus on preventive cardiac care, expansion of treatment in diabetic kidney disease, higher healthcare spending on chronic disease management. Major trends in the forecast period include rising prevalence of hypertension and cardiovascular disorders, growing reliance on ace inhibitors for first-line therapy, expansion of generic lisinopril prescriptions, increasing use in post-heart attack management, rising long-term treatment adherence in chronic care.

Global Lisinopril Market Segmentation

1) By Brand: Prinivil, Zestril, Other Brands 2) By Disease: Hypertension, Heart Failure, Heart Attack 3) By Dosage: Tablet, Liquid 4) By End-Users: Hospitals, Specialty Clinics Subsegments: 1) By Prinivil: Different Dosage Forms, Generic Versions Of Prinivil 2) By Zestril: Different Dosage Forms, Generic Versions Of Zestril 3) By Other Brands: International Brand Variants, Combination Drug Formulations

What Are The Drivers Of The Lisinopril Market?

The growing prevalence of cardiovascular diseases is expected to propel the growth of the lisinopril market going forward. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels. The growing prevalence of cardiovascular diseases can be attributed to several factors, such as population growth and aging, risk factors, and lack of implementation of proven prevention and treatment strategies. Lisinopril helps manage cardiovascular diseases primarily through its ability to lower blood pressure and reduce the strain on the heart and kidneys. This inhibits the production of angiotensin II, facilitates the dilation of blood vessels, reduces blood volume, and protects organs from damage. For instance, in May 2024, according to the Singapore Heart Foundation (SHF), a Singapore-based non-profit organization, ischemic heart diseases resulted in 5,302 deaths, showing a slight increase from 5,290 deaths in 2022. Therefore, the growing prevalence of cardiovascular diseases is driving the growth of the lisinopril industry. The increasing prevalence of hypertension is expected to propel the growth of the lisinopril market going forward. Hypertension, commonly known as high blood pressure, is a medical condition in which the force of the blood against the walls of the arteries is consistently too high. The rising prevalence of hypertension is due to an unhealthy diet, a sedentary lifestyle, an aging population, and long-term stress. Lisinopril is an effective medication for managing hypertension by blocking the formation of angiotensin II, leading to the relaxation of blood vessels, reduced blood volume, and lower blood pressure. For instance, in March 2023, The World Health Organization, a Switzerland-based health organization, around 1.28 billion adults aged 30–79 years worldwide had hypertension in 2023. Therefore, the increasing prevalence of hypertension drives the lisinopril industry.

Key Players In The Global Lisinopril Market

Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zydus Cadila Healthcare Ltd., Hetero Ltd., Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., Sandoz International GmbH

What Are Latest Mergers And Acquisitions In The Lisinopril Market?

In January 2024, Sun Pharmaceutical Industries Limited, an Indian-based pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd for $347.73 million. This acquisition marked sun pharma's move to expand its portfolio by incorporating Taro's expertise in providing generic and specialty medicines, active pharmaceutical ingredients (Apis), and over-the-counter products. Taro Pharmaceutical Industries Ltd. is a US-based company that offers lisinopril.

Regional Outlook

North America was the largest region in the lisinopril market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lisinopril Market?

The lisinopril market consists of sales of prinivil, qbrelis, zestoretic, zestril and apo-lisinopril. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lisinopril Market Report 2026?

The lisinopril market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lisinopril industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.